<DOC>
	<DOCNO>NCT00231075</DOCNO>
	<brief_summary>Safety Efficacy Paraplatin combination Taxol patient 70 year old epithelial ovary cancer F.I.G.O . stage III IV .</brief_summary>
	<brief_title>Evaluation Safety Efficacy Paraplatin Combination With Taxol Patients 70 Years Older With Ovary Cancer F.I.G.O . Stages III-IV</brief_title>
	<detailed_description>The Main objective study evaluate faisibility chemotherapy Paraplatin combination Taxol patient 70 year old epithelial ovary cancer F.I.G.O . stage III IV determine principal predictive factor feasibility .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histological cytological proven diagnosis epithelial ovary cancer F.I.G.O stag III IV ( cytological proven diagnosis available : malignant cell pelvis tumoral mass increase CA125 must diagnose simultaneously ) Patient age &gt; 70 year Neutrophil polynuclears &gt; 1500/mm3 Platelets &gt; 100 000/mm3 No clinical icterus Life expectancy least 3 month Previous diagnosis malignancy Previous chemotherapy treatment Previous radiotherapy Hypersensitivity product contain Cremophore EL Hepatic value : bilirubine &gt; 2*LSN , SGOTSGPT &gt; 2*LSN and/or Alkalin phosphatase &gt; 3*LSN Myocardiopathy arrhythmia</criteria>
	<gender>Female</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Epithelial ovary cancer F.I.G.O . stage III IV</keyword>
	<keyword>70 year old</keyword>
</DOC>